Payment overview · 2025
General Payments
$164.11
8 reported records · 6 companies
Healthcare provider profile · identity verified
Eric D Norton, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARTANBURG, SC · NPI 1932152139
Verified facts
What the public records show
CMS Open Payments records show Eric D Norton, MD received $164.11 in general payments during 2025 across 8 reported records.
Dexcom, Inc. accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $67.59 | 41.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.17 | 14.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.35 | 12.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.59 | 10.7% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $17.35 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.06 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.11 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $67.59 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1233 | 361 |
| Amlodipine Besylate | Amlodipine Besylate | 898 | 256 |
| Losartan Potassium | Losartan Potassium | 586 | 175 |
| Hydrochlorothiazide | Hydrochlorothiazide | 469 | 139 |
| Metformin Hcl | Metformin Hcl | 330 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 105 |
| Omeprazole | Omeprazole | 289 | 86 |
| Gabapentin | Gabapentin | 279 | 92 |
| Lisinopril | Lisinopril | 257 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 221 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 63 |
| Tramadol Hcl | Tramadol Hcl | 203 | 48 |
| Glimepiride | Glimepiride | 202 | 56 |
| Carvedilol | Carvedilol | 184 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 35 |
| Furosemide | Furosemide | 172 | 59 |
| Valsartan | Valsartan | 167 | 47 |
| Trazodone Hcl | Trazodone Hcl | 165 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 55 |
| Famotidine | Famotidine | 161 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 48 |
| Lorazepam | Lorazepam | 155 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 41 |
| Sertraline Hcl | Sertraline Hcl | 138 | 34 |
| Simvastatin | Simvastatin | 125 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 36 |
| Alprazolam | Alprazolam | 120 | 16 |
| Alendronate Sodium | Alendronate Sodium | 118 | 38 |
| Metformin Hcl Er | Metformin Hcl | 111 | 41 |
| Celecoxib | Celecoxib | 106 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 30 |
| Potassium Chloride | Potassium Chloride | 102 | 36 |
| Eliquis | Apixaban | 100 | 25 |
| Allopurinol | Allopurinol | 99 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 22 |
| Fenofibrate | Fenofibrate | 86 | 23 |
| Spironolactone | Spironolactone | 85 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 26 |
| Montelukast Sodium | Montelukast Sodium | 83 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 32 |
| Ozempic | Semaglutide | 77 | 20 |
| Finasteride | Finasteride | 76 | 23 |
| Jardiance | Empagliflozin | 73 | 19 |
| Bupropion Xl | Bupropion Hcl | 68 | 23 |
| Ezetimibe | Ezetimibe | 68 | 23 |
| Meloxicam | Meloxicam | 68 | 27 |
| Diazepam | Diazepam | 65 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 25 |
| Mirtazapine | Mirtazapine | 63 | 20 |
| Pregabalin | Pregabalin | 63 | 13 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 19 |
| Benazepril Hcl | Benazepril Hcl | 57 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 25 |
| Terazosin Hcl | Terazosin Hcl | 54 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 12 |
| Memantine Hcl | Memantine Hcl | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 48 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 17 |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Temazepam | Temazepam | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Tradjenta | Linagliptin | 39 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 11 |
| Nitroglycerin | Nitroglycerin | 37 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Colchicine | Colchicine | 36 | 14 |
| Atenolol | Atenolol | 35 | 12 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 24 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | 11 |
| Meclizine Hcl | Meclizine Hcl | 31 | 16 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 11 |
| Cefdinir | Cefdinir | 29 | 29 |
| Fluconazole | Fluconazole | 28 | 20 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 14 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Prednisone | Prednisone | 16 | 15 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Estradiol | Estradiol | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164.11 · 8 records | Dexcom, Inc. | Dexcom G6 Transmitter, Exablate, FREESTYLE LIBRE 3, INSPIRE, KRYSTEXXA, NURTEC ODT, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error